



London, UK, 3 December 2013

Edison initiates coverage of Magforce, the German cancer nanotechnology company

**Edison Investment Research, a leading international investment research firm, announces the initiation of coverage of MagForce (MF6), a German firm with a European approved nanotechnology-based therapy to treat brain tumours.**

Edison's report, *Coming out in Force*, was published on 27 November and examines MagForce's ability to execute on its strategy to increase uptake of its novel NanoTherm therapy, already approved in Europe for brain cancer. MagForce has worked closely with a number of key opinion leaders to design a new glioblastoma (GBM) study, starting imminently, to help increase physician acceptance and awareness of the therapy. It also intends to enter the US market and develop NanoTherm therapy for prostate cancer. Edison's risk-adjusted valuation is €197m or €8.2/share.

For the full report see: [www.edisoninvestmentresearch.com/research/company/magforce](http://www.edisoninvestmentresearch.com/research/company/magforce)

### About Edison Investment Research

The launch of coverage on MagForce is part of a programme of research initiations on biopharmaceutical companies exposed to global market opportunities. Edison provides detailed research coverage on more than 150 pharmaceutical and healthcare companies in Europe, North America, Australia and New Zealand. Its team of over 100 analysts and investment professionals works with leading companies, fund managers and investment banks worldwide to support its capital markets activity. It provides services to more than 400 retained corporate and investor clients from offices in London, New York, Frankfurt, Sydney and Wellington. All reports Edison publishes are available to download free of charge from its website [www.edisongroup.com](http://www.edisongroup.com).

Edison is authorised and regulated by the Financial Services Authority ([www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584](http://www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584)). Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

### For more information please contact:

Dr Philippa Gardner                      Edison Investment Research                      +44 (0)20 3681 2521

[healthcare@edisongroup.com](mailto:healthcare@edisongroup.com)

### About Magforce

MagForce is a German firm with a European approved nanotechnology-based therapy to treat brain tumours. NanoTherm therapy consists of nanoparticle injection into the tumour, activated by an external magnetic field, producing heat and thermally destroying or sensitising the tumour.

Frankfurt +49 (0)69 78 8076 960  
Schumannstrasse 34b  
60325 Frankfurt  
Germany

London +44 (0)20 3077 5700  
280 High Holborn  
London, WC1V 7EE  
United Kingdom

New York +1 646 653 7026  
245 Park Avenue, 39th Floor  
10167, New York  
US

Sydney +61 (0)2 9258 1162  
Level 33, Australia Square  
264 George St, Sydney  
NSW 2000, Australia

Wellington +64 (0)4 8948 555  
Level 15, 171 Featherston St  
Wellington 6011  
New Zealand